Stay updated with breaking news from Anna Sureda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from phase 1/2 EPCORE NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d...